McNamara Financial Services Inc. Purchases 275 Shares of Johnson & Johnson (NYSE:JNJ)

McNamara Financial Services Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 13.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,265 shares of the company’s stock after acquiring an additional 275 shares during the period. McNamara Financial Services Inc.’s holdings in Johnson & Johnson were worth $376,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in JNJ. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson during the 4th quarter worth $32,000. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $33,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $36,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $155.02 on Friday. The company has a 50 day moving average of $153.59 and a 200 day moving average of $153.68. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $372.99 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. Raymond James dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Wall Street Zen cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.